Article Text

L22 Intranasal application of NPY and NPY13–36 ameliorate disease pathology in R6/2 mouse model of huntington’s disease
  1. Oluwaseun Fatoba1,2,
  2. Eugen Kloster3,
  3. Carsten Saft4,
  4. Ralf Gold1,4,
  5. Larissa Arning#,3,
  6. Gisa Ellrichmann#,4
  1. 1International Graduate School of Neuroscience, Ruhr-University Bochum, Bochum, Germany
  2. 2Centre for Clinical Research, Ruhr-University Bochum, Bochum, Germany
  3. 3Department of Human Genetics, Ruhr-University Bochum, Bochum, Germany
  4. 4Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
  5. #authors share last authorship


Background Neuropeptide Y (NPY) is a potent neuromodulator that is expressed throughout the central nervous system. The sparing and persistence increase in NPY-expressing striatal interneurons with advancing disease have been implicated to correlate with striatal pathology in both Huntington’s disease (HD) patients and animal models of HD. However, the potential roles of intense expression of NPY in HD pathology still remain under-explored.

Aims To investigate whether activation of NPY-Y2 receptor using NPY and selective Y2 receptor ligands could ameliorate behavioural deficits and neuropathology in R6/2 mouse model of HD.

Methods/techniques NPY and selective Y2 receptor agonist NPY13-36 were intranasally administered to R6/2 mice, five days in a week, beginning from 4 weeks of age until 12 weeks of age. In the second study, R6/2 mice received daily intraperitoneal administration of selective non-peptide Y2 receptor antagonist (SF-31) to selectively block Y2 receptor.

Results/outcome Intranasal application of NPY showed significant increase in rotarod performance compared to saline and SF-31 treated R6/2 mice (pp < 0.05 and **p < 0.01 at 8 and 12 weeks of age respectively, n = 10). However, treatment with NPY13-36 showed a clear trend towards increased rotarod performance at 12 weeks of age compared with the saline and SF-31 treated R6/2 mice but the difference did not reach significance. Also, we found no statistically significant difference in body weight loss between the groups, contrasting with previous data obtained with single intracerebroventricular (ICV) injection of NPY in R6/2 mice. Furthermore, intranasal application NPY or NPY13-36 led to decrease in mutant Huntingtin (Htt) aggregation and mediated increase in dopamine-and cAMP regulated phosphoprotein (DARPP-32) and brain derived neurotrophic factor (BDNF) levels. Additionally, we found that NPY and NPY13-36 attenuate microglial activation and expression of interleukin-1beta mRNA expression.

Conclusion Taken together, our findings suggest that targeting NPY-Y2 receptor might be a potential neuroprotective therapy for HD and other neurodegenerative diseases.

  • NPY
  • NPY13-36
  • R6/2 mice
  • Neuroprotection

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.